Prostate Cancer

In this episode of The UroOnc Minute, Adam B. Weiner, MD, speaks with Alexander Light, MBBS, about evolving strategies for salvage treatment in patients with radiorecurrent prostate cancer.

Treatment with 177Lu-PSMA-617 may durably delay disease progression compared with deferred ADT in men with oligometastatic hormone-sensitive prostate cancer.

"Urologists today are armed with 2 guideline-supported modalities to reduce the burden of unnecessary biopsies while maintaining timely detection of clinically significant cancers," write the authors.

The device will be available over the counter in the US, with anticipated availability beginning in April 2026.

At 3 years, transdermal estradiol demonstrated noninferior MFS compared with standard LHRH agonists.

The study is evaluating the safety, tolerability, whole-body distribution, and preliminary clinical activity of RAD 402 in patients with locally advanced or metastatic castration-resistant prostate cancer.

Andrew J. Armstrong, MD, MS, highlights updated recommendations from the Prostate Cancer Working Group 4.

In this episode of The UroOnc Minute, host Adam B. Weiner, MD, is joined by Veeru Kasivisvanathan, MBBS, MSc, PhD, FRCS, to discuss the role of biparametric vs multiparametric MRI for prostate cancer detection.

The European Commission is expected to have a final decision on the application in the second quarter of 2026.

Neha Vapiwala, MD, pointed to the shift toward more personalized approaches and the expanding role of radiopharmaceutical therapies.

Topline results from the TALAPRO-3 study showed that adding talazoparib to enzalutamide improved rPFS for patients with HRR-mutated mCSPC.

Enolen implants demonstrated minimal systemic drug exposure and early signals of tumor volume reduction in localized prostate cancer.

The OPTIMUM randomized trial demonstrated that microultrasonography-guided biopsy is noninferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer, with a streamlined in-office workflow, a manageable learning curve, and substantially lower cost that may help address diagnostic access gaps worldwide.

Alicia Morgans, MD, MPH, shares findings from a real-world study assessing darolutamide or abiraterone in combination with ADT plus docetaxel for mHSPC.

Lutetium-177 rosopatamab tetraxetan demonstrated an acceptable safety and tolerability profile with no new safety signals in patients with PSMA-positive mCRPC.

Results from the AMPLIFY trial are intended to support an FDA submission seeking approval of 64Cu-SAR-bisPSMA as a diagnostic imaging agent for BCR of prostate cancer.

According to Lantheus, Pylarify TruVu is formulated to improve product stability at higher radioactive concentrations, facilitating more efficient manufacturing and distribution.

Fred Saad, MD, FRCP, highlights the background and key findings from the phase 1 PAnTHa study.

“Biochemical responses were seen at all dose levels, with an overall PSA50 response of 62% and a PSA90 response of 40%," according to Fred Saad, CQ, MD, FRCS, FCAHS.

Karim Fizazi, MD, PhD, reported that the 9-year prostate cancer-specific survival rate was 90% (95% CI, 86-94) in patients receiving cabazitaxel vs 89% (95% CI, 84-93) in patients not receiving cabazitaxel.

"Capivasertib in combination with abiraterone represents a potential first-in-class targeted treatment for patients with this now PTEN-defined metastatic APMN,” said Daniel J. George, MD.

Stacy Loeb, MD, MSc, discusses a study evaluating levels of at microplastics and nanoplastics in prostate cancer tissue.